In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control

Matthew B Stanbrook

doi:10.7326/J24-0014

In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control

Ann Intern Med. 2024 Apr;177(4):JC43. doi: 10.7326/J24-0014. Epub 2024 Apr 2.

Author

Matthew B Stanbrook¹

Affiliation

¹ Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada (M.B.S.).

PMID: 38560905
DOI: 10.7326/J24-0014

Abstract

Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986.

Publication types

Randomized Controlled Trial
Multicenter Study

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Disease Progression
Humans

Substances

Anti-Asthmatic Agents
benralizumab
Antibodies, Monoclonal, Humanized
Adrenal Cortex Hormones